<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03148756</url>
  </required_header>
  <id_info>
    <org_study_id>DAL-MD-09</org_study_id>
    <secondary_id>2016-004170-17</secondary_id>
    <nct_id>NCT03148756</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis</brief_title>
  <official_title>Phase 2, Open-Label, Randomized, Multicenter Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Documented Infective Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare dalbavancin to standard of care (SOC) antibiotic therapy for the
      completion of therapy in patients with complicated bacteremia or infective endocarditis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped due to business reasons.
  </why_stopped>
  <start_date type="Actual">May 12, 2017</start_date>
  <completion_date type="Actual">August 4, 2017</completion_date>
  <primary_completion_date type="Actual">August 4, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response at Day 84 in the ITT population</measure>
    <time_frame>At Day 84</time_frame>
    <description>Clinical response can be either success or failure. Success is defined as recovery without need for additional antibiotic therapy.
Failure is defined as:
requirement of additional antibiotic therapy
recurrent bacteremia
death up to Day 84
discontinuation of study drug due to adverse event (AE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome at Day 42 in the ITT and the CE populations</measure>
    <time_frame>At Day 42</time_frame>
    <description>Clinical outcome can be either Success or Failure. Success is defined as recovery without need for additional antibiotic therapy.
Failure is defined as:
requirement of additional antibiotic therapy
recurrent bacteremia
death up to Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 84 mortality in the safety population</measure>
    <time_frame>At Day 84</time_frame>
    <description>Day 84 mortality is measured by the number of deaths up to Day 84.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome at Day 84 in the CE population</measure>
    <time_frame>At Day 84</time_frame>
    <description>Clinical outcome can be either Success or Failure/Relapse. Success is defined as recovery without need for additional antibiotic therapy.
Failure/Relapse is defined as:
requirement of additional antibiotic therapy
new signs and symptoms after recovery at Day 42
recurrent bacteremia
patient considered as clinical failure at Day 42
death up to Day 84</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome by pathogen at Day 42 and Day 84 in the ITT and CE populations</measure>
    <time_frame>At Day 42 and Day 84</time_frame>
    <description>Clinical outcome by pathogen at Day 42 can be either Success or Failure. Success is defined as recovery without need for additional antibiotic therapy.
Failure is defined as:
requirement of additional antibiotic therapy
recurrent bacteremia
death up to Day 42
Clinical outcome by pathogen at Day 84 can be either Success or Failure/Relapse.
Success is defined as recovery without need for additional antibiotic therapy.
Failure/Relapse is defined as:
requirement of additional antibiotic therapy
new signs and symptoms after recovery at Day 42
recurrent bacteremia
patient defined as clinical failure at Day 42
death up to Day 84</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic outcome by pathogen at Day 42 and Day 84 in the ITT and CE populations</measure>
    <time_frame>At Day 42 and Day 84</time_frame>
    <description>Microbiological outcome can be either Microbiologic Success or Microbiologic Failure.
Microbiologic Success is defined as no further growth of baseline pathogen from blood cultures.
Microbiologic Failure is defined as:
further growth of baseline pathogen from 2 consecutive blood cultures leading to the discontinuation of study drug
isolation of the baseline pathogen from 2 consecutive blood cultures after initial clinical improvement (relapse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Infective Endocarditis, Bacteremia</condition>
  <arm_group>
    <arm_group_label>Dalbavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin</intervention_name>
    <description>Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8</description>
    <arm_group_label>Dalbavancin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of complicated bacteremia or infective endocarditis

          -  Gram-positive bacteremia at screening with MSSA, MRSA or Streptococci

          -  Treatment with standard of care antibiotics for 72 h - 10 days

          -  Defervescence for at least 24h and clearance of bacteremia from screening pathogen

        Exclusion Criteria:

          -  Embolic events

          -  History of prosthetic valve surgery, cardiac device or prosthetic joint

          -  Left-sided endocarditis due to S. aureus

          -  Large mobile vegetations (&gt;10 mm) on mitral valves

          -  Perivalvular abscess

          -  Uncomplicated bacteremia due to S. aureus

          -  Gram-negative bacteria or fungi in blood cultures

          -  Heart failure associated with endocarditis (LVEF &lt;40%)

          -  Intravascular material or removable infection source not intended to be removed within
             4 days postrandomization

          -  Planned valve replacement surgery within 3 days of randomization

          -  Refractory shock, significant hepatic insufficiency or severe leukopenia (ANC &lt; 500
             cells/mm3)

          -  Known osteomyelitis

          -  Hypersensitivity to dalbavancin or other drugs in glycopeptide class

          -  Infection with enterococci, coagulase-negative staphylococci, or with organism not
             susceptible to dalbavancin or vancomycin

          -  Immunosuppression/immune deficiency

          -  Concomitant systemic antibacterial therapy for gram-positive infection other than that
             allowed in protocol

          -  Pregnant or nursing females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urania Rappo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Midway Immunology and Research Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Specialists of ATL, PC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Consultants</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Human Performance</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre of Singapore Pte Ltd</name>
      <address>
        <city>Singapore</city>
        <zip>168753</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>168753</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heart of England NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrook's Hospital Dept of Infectious Disease</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 OQQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals, NHS Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://AllerganClinicalTrials.com</url>
    <description>For information to locate a study location near you, please visit AllerganClinicalTrials.com</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Endocarditis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Dalbavancin</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

